Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protein acetylation in skeletal muscle mitochondria is involved in impaired fatty acid oxidation and exercise intolerance in heart failure.
Tsuda M, Fukushima A, Matsumoto J, Takada S, Kakutani N, Nambu H, Yamanashi K, Furihata T, Yokota T, Okita K, Kinugawa S, Anzai T. Tsuda M, et al. Among authors: yamanashi k. J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):844-859. doi: 10.1002/jcsm.12322. Epub 2018 Aug 30. J Cachexia Sarcopenia Muscle. 2018. PMID: 30168279 Free PMC article.
Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure.
Nambu H, Takada S, Fukushima A, Matsumoto J, Kakutani N, Maekawa S, Shirakawa R, Nakano I, Furihata T, Katayama T, Yamanashi K, Obata Y, Saito A, Yokota T, Kinugawa S. Nambu H, et al. Among authors: yamanashi k. Eur J Pharmacol. 2020 Jan 5;866:172810. doi: 10.1016/j.ejphar.2019.172810. Epub 2019 Nov 15. Eur J Pharmacol. 2020. PMID: 31738936 Free article.
Inhibition of xanthine oxidase in the acute phase of myocardial infarction prevents skeletal muscle abnormalities and exercise intolerance.
Nambu H, Takada S, Maekawa S, Matsumoto J, Kakutani N, Furihata T, Shirakawa R, Katayama T, Nakajima T, Yamanashi K, Obata Y, Nakano I, Tsuda M, Saito A, Fukushima A, Yokota T, Nio-Kobayashi J, Yasui H, Higashikawa K, Kuge Y, Anzai T, Sabe H, Kinugawa S. Nambu H, et al. Among authors: yamanashi k. Cardiovasc Res. 2021 Feb 22;117(3):805-819. doi: 10.1093/cvr/cvaa127. Cardiovasc Res. 2021. PMID: 32402072
Type 2 diabetes is an independent predictor of lowered peak aerobic capacity in heart failure patients with non-reduced or reduced left ventricular ejection fraction.
Abe T, Yokota T, Fukushima A, Kakutani N, Katayama T, Shirakawa R, Maekawa S, Nambu H, Obata Y, Yamanashi K, Nakano I, Takada S, Yokota I, Okita K, Kinugawa S, Anzai T. Abe T, et al. Among authors: yamanashi k. Cardiovasc Diabetol. 2020 Sep 19;19(1):142. doi: 10.1186/s12933-020-01114-4. Cardiovasc Diabetol. 2020. PMID: 32950064 Free PMC article.
61 results